Caribou Biosciences, Inc.
cariboubio.comWhat Do They Do?
Develops genome-edited, off-the-shelf CAR-T cell therapies for patients with blood cancers.
10-K for FY2025, filed Mar 5, 2026Our allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”) -T (“CAR-T”) cell therapy product candidates are manufactured in…View ↗
We are advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic…View ↗
Vispacabtagene regedleucel (“vispa-cel,” formerly CB-010): an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients…View ↗
How Do They Make Money?
Its revenue comes from licensing and collaboration agreements: partners pay upfront or annual fees for technology rights, research and development services, and milestone payments; it may also receive royalties on licensed-product sales. A standalone license can pay when rights are granted, while bundled services may pay as the work progresses.
10-K for FY2025, filed Mar 5, 2026To date, all of our revenue consists of licensing and collaboration revenue earned from collaboration and/or licensing agreements entered…View ↗
Our revenues are primarily derived through license and/or license and collaboration agreements. The terms of these types of agreements may…View ↗
If a license to intellectual property controlled by us is determined to be distinct from the other performance obligations identified in…View ↗
Certain of our license agreements include contingent milestone payments. Such milestone payments are typically payable when the…View ↗
Our license and/or collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based…View ↗
$11.2M
-
10-K for FY2025, filed Mar 5, 2026
$11.2M ↗
Who Are Their Customers?
Third-party licensees and collaborators obtain rights to Caribou's intellectual property; agreements may also cover research and development services or participation in research or governance committees.
10-K for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $148.1M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$148.3MView ↗
10-K for FY2025, filed Mar 5, 2026
−$148.1MView ↗
10-K for FY2025, filed Mar 5, 2026
−$112.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$24.3MView ↗
- ▼ −55% (Loss)
- vs −$54.1M in Q2 FY2025
-
Jun 11, 2026
Reported follow-up trial data for vispa-cel and CB-011
The optimized vispa-cel subgroup had an 82% overall response rate; Caribou said the planned pivotal trial design was aligned with the FDA.
Sources
8-K, filed Jun 11, 2026
On June 11, 2026, the Company announced long-term follow-up data from its ANTLER phase 1 clinical trial that evaluated vispa-cel, an…View ↗
Growing. Revenue grew 16% in 4 years, from $9.6M in FY2021 to $11.2M in FY2025, about 4% a year.
A narrower cell-therapy pipeline
The older report described CAR-T and CAR-NK programs for blood cancers and solid tumors, including therapies developed for AbbVie. The latest report focuses on allogeneic CAR-T candidates for blood cancers and says it discontinued preclinical research.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) genome-editing biopharmaceutical company…View ↗
Our pipeline includes allogeneic cell therapies from our CAR-T and CAR-NK platforms. We currently are advancing four wholly owned programs…View ↗
Additionally, we are developing allogeneic CAR-NK cell therapies derived from genome-edited induced pluripotent stem cells (“iPSCs”) for…View ↗
In February 2021, we entered into a Collaboration and License Agreement (as amended, the “AbbVie Agreement”) with AbbVie to develop two…View ↗
Who Do They Compete With?
Competes with Novartis, Kite Pharma, Bristol-Myers Squibb, Allogene Therapeutics, Atara Biotherapeutics, AvenCell Therapeutics, Cellectis, CRISPR Therapeutics, Fate Therapeutics, Sana Biotechnology, Legend Biotech, Arcellx, Cabaletta Bio, Intellia Therapeutics, and AbbVie
10-K for FY2025, filed Mar 5, 2026Autologous T cell therapy: Autologous T cell therapies directed at CD19 have been commercialized by Novartis AG (Kymriah®), Kite Pharma…View ↗
Loading...
